Funding for this research was provided by:
Conquer Cancer Foundation (ASCO YIA)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA215797)
Article History
Received: 16 July 2020
Revised: 5 March 2021
Accepted: 30 March 2021
First Online: 28 April 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: M.M.R. and K.A.B. report no competing interests. N.M.I. reports consulting and speaking fees from Novartis and Seattle Genetics unrelated to this work.
: This research was supported in part through the National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant P30 CA008748. M.M.R. is supported through the Conquer Cancer ASCO YIA award. K.A.B. is supported through NIH R01 CA215797 grant. N.M.I. is supported through the NIH 1 R01CA235711 grant, the Breast Cancer Research Foundation, American Cancer Society, and the Kat’s Ribbon of Hope Foundation.